ELEKTA INITIATES REPURCHASE OF OWN SHARES

ELEKTA INITIATES REPURCHASE OF OWN SHARES

PRESS RELEASE			
Stockholm, January 24, 2008

Elekta has on January 24, 2008, repurchased 100,000 B shares at an average price
of SEK 104.79. Elekta's current holding of own shares (treasury stock) amounts
to 1 730 871 B-shares, including 1,630,871 B shares, which are in the process of
being cancelled according to the decision by the AGM on September 25.

The total number of shares in Elekta as of December 31, 2007 amounts to
93,903,316 divided between 3,562,500 A shares and 90,340,816 B shares.

The repurchases currently being carried out follows the Board's decision on
January 23, 2008, to mandate executive management to initiate on appropriate
occasions the repurchase of shares amounting up to SEK 100 M, but maximized to
1,200,000 shares.

For information regarding implementation of additional purchases within this
mandate, Elekta offers reference continually to
http://omxgroup.com/nordicexchange.

Purchases will be made on the Nordic Exchange and at a price within the
registered price interval at the time of each purchase. Purchases may be made
during the period until the next Annual General Meeting. Elekta's Board intends
to suggest to the AGM that repurchased shares are cancelled.






********

For further information, please contact:

Peter Ejemyr, Group VP Corporate Communications, Elekta AB
Tel: +46 733 611 000 (mobile), e-mail: peter.ejemyr@elekta.com  

About Elekta

Elekta is an international medical technology group, providing oncologists,
radiation therapists, neurosurgeons and many other medical specialists with
state of the art tools to fight serious disease.

Elekta provides advanced clinical solutions, comprehensive management and
information systems as well as services for improved cancer care and management
of brain disorders. 

Elekta's systems and solutions are used in over 4,500 hospitals around the
world. Clinical and information management solutions include, among others,
Leksell Gamma Knife® for non-invasive treatment of brain disorders, Elekta
Axesse™ and Elekta Synergy® for stereotactic and image guided radiation therapy
and radiosurgery as well as the MOSAIQ™ suite of software for image-enabled EMR
and efficient management of clinical and patient data.

With over 2,000 employees globally, the corporate headquarter is located in
Stockholm, Sweden and the company is listed on the Nordic Exchange under the
ticker EKTAb. More information about Elekta can be found at www.elekta.com.